CGEM Stock Price, Cullinan Management, . Quote, Chart

Market Summary

USD16.65+1.02

Market Closed

6.53%

CGEM Stock Price

View Fullscreen

CGEM RSI Chart

CGEM Valuation

Market Cap

717.0M

Price/Earnings (Trailing)

-4.68

Price/Sales (Trailing)

6.78

EV/EBITDA

-3.67

Price/Free Cashflow

-5.33

CGEM Price/Sales (Trailing)

CGEM Profitability

EBT Margin

-157.52%

Return on Equity

-33.78%

Return on Assets

-31.65%

Free Cashflow Yield

-18.76%

CGEM Fundamentals

CGEM Revenue

Revenue (TTM)

107.4M

CGEM Earnings

Earnings (TTM)

-153.3M

Earnings Growth (Yr)

-57.97%

Earnings Growth (Qtr)

39.48%

Breaking Down CGEM Revenue

Last 7 days

-3.9%

Last 30 days

0.4%

Last 90 days

33.2%

Trailing 12 Months

55.9%

How does CGEM drawdown profile look like?

CGEM Financial Health

Current Ratio

17.07

Debt/Equity

0

Debt/Cashflow

-67.14

CGEM Investor Care

Buy Backs (1Y)

6.54%

Diluted EPS (TTM)

-3.69

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q2	Q3	Q4
2023	0	0	0
2022	173.6M	140.5M	107.4M
2021	0	0	18.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Cullinan Management, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 22, 2024	jones jeffrey alan	acquired	-	-	62,500	chief medical officer
Feb 22, 2024	savill corrine	acquired	-	-	37,500	chief business officer
Feb 22, 2024	ahmed nadim	acquired	-	-	160,000	president and ceo
Feb 22, 2024	trigilio jeffrey	acquired	-	-	50,000	chief financial officer
Feb 22, 2024	sumer jacquelyn l	acquired	-	-	50,000	chief legal officer
Feb 22, 2024	michaelson jennifer	acquired	-	-	50,000	chief scientific officer
Feb 01, 2024	savill corrine	sold	-647,200	16.18	-40,000	chief business officer
Feb 01, 2024	savill corrine	acquired	172,000	4.3	40,000	chief business officer
Jan 29, 2024	savill corrine	acquired	172,000	4.3	40,000	chief business officer
Jan 29, 2024	savill corrine	sold	-563,600	14.09	-40,000	chief business officer

Which funds bought or sold CGEM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	15,204	135,904	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	19.71	143,690	287,124	0.01%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	unchanged	-	246	613	-%
Apr 05, 2024	CWM, LLC	added	13.79	1,000	1,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	20.39	2,214	8,452	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	6.25	28.00	173	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.91	2,769,780	18,051,000	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	198	1,835,760	2,615,060	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	0.08	1,418,480	12,600,600	0.05%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	52.91	94,000	225,000	-%

Are Funds Buying or Selling CGEM?

Are funds buying CGEM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CGEM

No. of Funds

Unveiling Cullinan Management, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	jovan-embiricos morana	1.10%	468,696	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	6.5%	2,870,427	SC 13G/A
Feb 14, 2024	blue owl capital holdings lp	7.99%	3,419,842	SC 13G
Feb 13, 2024	vanguard group inc	4.14%	1,771,443	SC 13G/A
Feb 06, 2024	franklin resources inc	7.7%	3,281,280	SC 13G
Jan 29, 2024	blackrock inc.	5.8%	2,462,274	SC 13G
Sep 07, 2023	blackrock inc.	4.8%	2,036,651	SC 13G/A
Feb 15, 2023	jovan-embiricos morana	3.4%	1,577,440	SC 13G/A
Feb 14, 2023	biotechnology value fund l p	8.9%	4,058,854	SC 13G/A
Feb 13, 2023	chi advisors llc	7.25%	3,317,544	SC 13G/A

Recent SEC filings of Cullinan Management, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	8-K	Current Report
Apr 02, 2024	3	Insider Trading
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 14, 2024	S-8	Employee Benefits Plan
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to Cullinan Management, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	2.33%	-21.90%	-8.74	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.36%	-10.84%	24.31	4.36	85.90%	-14.05%
NVAX	587.8M	983.7M	-10.64%	-48.02%	-1.08	0.6	-50.36%	17.16%
CRBP	396.0M	881.7K	8.01%	271.09%	-8.88	466.16	-77.61%	-5.33%
INO	242.4M	4.9M	-10.76%	0.48%	-1.79	49.8	-54.97%	51.71%
IBIO	6.7M	2.1M	76.15%	62.71%	-0.25	2.14	-13.45%	66.37%

Cullinan Management, Inc. News

Latest updates

Cullinan Management, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2021Q4	2021Q3	2021Q2	2021Q1
Revenue	-	-	-	-	174	-	-	-	19.00
Operating Expenses	39.5%	45.00	33.00	30.00	37.00	34.00	18.00	17.00	18.00
S&GA Expenses	-5.8%	11.00	11.00	10.00	11.00	13.00	6.00	5.00	5.00
R&D Expenses	63.4%	35.00	21.00	20.00	26.00	21.00	13.00	12.00	12.00
EBITDA Margin	-211.5%	-1.57*	1.41*	1.04*	0.89*	-3.56*	-	-	-
Income Taxes	-651.2%	-14.12	-1.88	-2.50	66.00	-	-	-	-
Earnings Before Taxes	-37.1%	-39.68	-28.95	-27.41	240	-34.21	-18.26	-16.44	1.00
EBT Margin	-211.8%	-1.58*	1.41*	1.04*	0.89*	-3.56*	-	-	-
Net Income	-Infinity%	-23.71	-	-24.80	174	-32.86	-17.35	-16.44	1.00
Net Income Margin	-238.8%	-1.43*	1.03*	0.74*	0.64*	-3.44*	-	-	-
Free Cashflow	29.9%	-18.13	-25.86	-54.60	-25.42	-15.17	-10.55	-16.19	-1.51

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-2.1%	484	495	522	515	561	617	667	437	437	453	464	480	215
Current Assets	0.7%	480	477	498	399	474	582	623	322	297	329	344	447	212
Cash Equivalents	51.8%	98.00	65.00	142	122	156	243	354	76.00	60.00	88.00	124	294	168
Net PPE	-7.2%	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	17.0%	30.00	26.00	22.00	29.00	26.00	31.00	63.00	18.00	12.00	8.00	6.00	10.00	14.00
Current Liabilities	20.0%	28.00	23.00	20.00	26.00	22.00	27.00	62.00	17.00	12.00	8.00	6.00	10.00	14.00
Long Term Debt	1042.9%	2.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-3.2%	454	469	500	486	535	586	605	419	425	445	459	470	200
Retained Earnings	-13.4%	-200	-177	-137	-105	-47.69	-20.91	4.00	-171	-158	-126	-109	-93.41	-93.34
Additional Paid-In Capital	1.2%	655	647	639	593	585	611	604	593	585	570	565	560	292
Shares Outstanding	0.3%	43.00	43.00	43.00	39.00	46.00	46.00	45.00	44.00	44.00	43.00	43.00	42.00	-
Minority Interest	-	0.00	-	-	-	-	-	0.00	1.00	0.00	2.00	3.00	3.00	1.00
Float	-	-	-	374	-	-	-	376	-	-	-	717	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	46.9%	-18.13	-34.14	-31.01	-51.00	-24.98	-54.35	-25.42	-21.91	-15.17	-10.55	-16.20	-1.51	-9.44	-9.07	-6.25	-5.01
Share Based Compensation	-2.9%	8.00	8.00	8.00	7.00	-	5.00	9.00	7.00	12.00	5.00	4.00	4.00	-	-	-	-
Cashflow From Investing	219.8%	51.00	-42.96	12.00	15.00	-28.61	-57.98	301	35.00	-15.86	-25.59	-154	-137	11.00	-1.94	12.00	-26.89
Cashflow From Financing	121.4%	0.00	0.00	39.00	2.00	-32.91	1.00	2.00	4.00	3.00	1.00	1.00	265	125	1.00	-	14.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	-	-	0.00

CGEM Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 148,156	$ 91,948
General and administrative	42,493	40,189
Total operating expenses	190,649	132,137
Impairment of long-lived assets	440	0
Gain on sale of Cullinan Pearl	0	276,785
Income (loss) from operations	(191,089)	144,648
Other income (expense):
Interest income	21,627	6,611
Other income (expense), net	239	57
Net income (loss) before income taxes	(169,223)	151,316
Income tax expense (benefit)	(14,122)	42,121
Net income (loss)	(155,101)	109,195
Net loss attributable to noncontrolling interests	(1,939)	(2,019)
Net income (loss) attributable to common stockholders of Cullinan	(153,162)	111,214
Comprehensive income (loss):
Net income (loss)	(155,101)	109,195
Unrealized gain (loss) on investments	2,472	(1,763)
Comprehensive income (loss)	(152,629)	107,432
Comprehensive loss attributable to noncontrolling interests	(1,939)	(2,019)
Comprehensive income (loss) attributable to Cullinan	$ (150,690)	$ 109,451
Net income (loss) per share attributable to common stockholders of Cullinan:
Basic	$ (3.69)	$ 2.46
Diluted	$ (3.69)	$ 2.38
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders of Cullinan:
Basic	41,550	45,164
Diluted	41,550	46,640

CGEM Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 98,434	$ 156,152
Short-term investments	368,633	311,140
Prepaid expenses and other current assets	13,124	7,180
Total current assets	480,191	474,472
Property and equipment, net	989	1,174
Operating lease right-of-use assets	2,543	4,130
Other assets	459	459
Long-term investments	0	80,882
Total assets	484,182	561,117
Current liabilities:
Accounts payable	2,493	2,660
Accrued expenses and other current liabilities	24,204	14,135
Income tax payable	0	4,282
Operating lease liabilities, current	1,440	1,421
Total current liabilities	28,137	22,498
Long-term liabilities:
Lease liabilities, non-current	2,150	3,590
Total liabilities	30,287	26,088
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2023 and 2022; 647,500 and no shares issued and outstanding as of December 31, 2023 and 2022, respectively.	0	0
Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2023 and 2022; 42,900,083 and 45,796,449 shares issued and outstanding as of December 31, 2023 and 2022, respectively.	4	5
Additional paid-in capital	654,685	585,320
Accumulated other comprehensive loss	(129)	(2,601)
Accumulated deficit	(200,857)	(47,695)
Total Cullinan stockholders' equity	453,703	535,029
Noncontrolling interests	192	0
Total stockholders' equity	453,895	535,029
Total liabilities and stockholders' equity	$ 484,182	$ 561,117

About Cullinan Management, Inc.

Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Nadim Ahmed
WEBSITE	cullinanoncology.com
INDUSTRY	Biotechnology
EMPLOYEES	62

Cullinan Management, Inc. Frequently Asked Questions

What is the ticker symbol for Cullinan Management, Inc.? What does CGEM stand for in stocks?

CGEM is the stock ticker symbol of Cullinan Management, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cullinan Management, Inc. (CGEM)?

As of Tue Apr 23 2024, market cap of Cullinan Management, Inc. is 717.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CGEM stock?

You can check CGEM's fair value in chart for subscribers.

What is the fair value of CGEM stock?

You can check CGEM's fair value in chart for subscribers. The fair value of Cullinan Management, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cullinan Management, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CGEM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cullinan Management, Inc. a good stock to buy?

The fair value guage provides a quick view whether CGEM is over valued or under valued. Whether Cullinan Management, Inc. is cheap or expensive depends on the assumptions which impact Cullinan Management, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CGEM.

What is Cullinan Management, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, CGEM's PE ratio (Price to Earnings) is -4.68 and Price to Sales (PS) ratio is 6.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGEM PE ratio will change depending on the future growth rate expectations of investors.